Comparing two assays for clinical genomic profiling: the devil is in the data [Letter of clarification]

This article was published in the following Dove Press journal:
OncoTargets and Therapy
18 September 2015
Number of times this article has been viewed

Dear editor

It has come to our attention that the second and fourth paragraph of our Authors’ reply1 may be misconstrued as an endorsement of the Paradigm Cancer Diagnostics (PCDx) test by Cancer Treatment Centers of America, Western Regional Medical Center, Goodyear, AZ, USA. This was not our intention. We stand by the interpretation of the results of the original manuscript and the remainder of the content of the Authors’ reply. We welcome a more robust clinical comparison of these two platforms, as well as any other platform that may improve the clinical decision-making and outcomes for patients with advanced cancer.

Disclosure

GJW is a clinical oncology advisor to Viomics and a scientific and medical advisor to Paradigm. All authors had control of the data and information submitted for the reply to the letter to the editor. The authors report no other conflicts of interest in this communication.

Reference


Correspondence: Glen J Weiss
Cancer Treatment Centers of America, Western Regional Medical Center, Goodyear, AZ, USA

Tel +1 623 207 3000
Fax +1 623 207 3003
Email glen.weiss@ctca-hope.com

Dove Medical Press encourages responsible, free and frank academic debate. The content of the OncoTargets and Therapy ‘letters to the editor’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the OncoTargets and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.